Suchergebnis | Hamburg Open Science

Facetten

25 Einträge gefunden

Cortisol, DHEA and DHEA-S during exposure therapy in patients with obsessive-compulsive disorder – secretion patterns and prediction of treatment response
2020 - Forschungsinformationssystem des UKE - frei zugänglich
Impact of physical or sexual childhood abuse on plasma DHEA, DHEA-S and cortisol in a low-dose dexamethasone suppression test and on cardiovascular risk parameters in adult patients with major depression or anxiety disorders
2018 - Forschungsinformationssystem des UKE
[Long-term consequences of flight and expulsion in former refugee children].
2011 - Forschungsinformationssystem des UKE
Decreased recognition of negative affect after selective serotonin reuptake inhibition is dependent on genotype.
2010 - Forschungsinformationssystem des UKE
CCK-4: Psychophysiological conditioning elicits features of spontaneous panic attacks.
2010 - Forschungsinformationssystem des UKE
Influence of exogenous atrial natriuretic peptide on the nocturnal hypothalamic-pituitary-adrenal axis and sleep in healthy men.
2010 - Forschungsinformationssystem des UKE
Does 5-HTTLPR genotype influence willingness to participate in panic challenges?
2009 - Forschungsinformationssystem des UKE
Increased DHEA and DHEA-S plasma levels in patients with post-traumatic stress disorder and a history of childhood abuse.
2009 - Forschungsinformationssystem des UKE
Modulation of the mineralocorticoid receptor as add-on treatment in depression: a randomized, double-blind, placebo-controlled proof-of-concept study.
2009 - Forschungsinformationssystem des UKE
The selective serotonin re-uptake inhibitor escitalopram modulates the panic response to cholecystokinin tetrapeptide in healthy men depending on 5-HTTLPR genotype.
2009 - Forschungsinformationssystem des UKE
A combined dexamethasone/corticotropin-releasing hormone test in patients with chronic PTSD--first preliminary results.
2008 - Forschungsinformationssystem des UKE
No effect of six weeks of treatment with escitalopram on mood in healthy volunteers--irrespective of genotype for the promoter of the serotonin transporter.
2008 - Forschungsinformationssystem des UKE
Blockade of the mineralocorticoid receptor in healthy men: effects on experimentally induced panic symptoms, stress hormones, and cognition.
2007 - Forschungsinformationssystem des UKE
Mineralocorticoid receptor function in posttraumatic stress disorder after pretreatment with metyrapone.
2006 - Forschungsinformationssystem des UKE
Overnight metyrapone and combined dexamethasone/metyrapone tests in post-traumatic stress disorder: preliminary findings.
2004 - Forschungsinformationssystem des UKE
Valproate monotherapy in the treatment of civilian patients with non-combat-related posttraumatic stress disorder: an open-label study.
2004 - Forschungsinformationssystem des UKE
Metyrapone tests in patients with panic disorder.
2004 - Forschungsinformationssystem des UKE
Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial.
2004 - Forschungsinformationssystem des UKE
The mineralocorticoid receptor agonist, fludrocortisone, inhibits pituitary-adrenal activity in humans after pre-treatment with metyrapone.
2003 - Forschungsinformationssystem des UKE
Endocrine and cardiovascular responses to corticotropin-releasing hormone in patients with posttraumatic stress disorder: a role for atrial natriuretic peptide?
2003 - Forschungsinformationssystem des UKE

Aktive Facetten

Facetten

Zugriff

Einrichtung

Medientyp

Karte

Erscheinungsjahr

Autor/in

Sprache

Cortisol, DHEA and DHEA-S during exposure therapy in patients with obsessive-compulsive disorder – secretion patterns and prediction of treatment response

Impact of physical or sexual childhood abuse on plasma DHEA, DHEA-S and cortisol in a low-dose dexamethasone suppression test and on cardiovascular risk parameters in adult patients with major depression or anxiety disorders

[Long-term consequences of flight and expulsion in former refugee children].

Decreased recognition of negative affect after selective serotonin reuptake inhibition is dependent on genotype.

CCK-4: Psychophysiological conditioning elicits features of spontaneous panic attacks.

Influence of exogenous atrial natriuretic peptide on the nocturnal hypothalamic-pituitary-adrenal axis and sleep in healthy men.

Does 5-HTTLPR genotype influence willingness to participate in panic challenges?

Increased DHEA and DHEA-S plasma levels in patients with post-traumatic stress disorder and a history of childhood abuse.

Modulation of the mineralocorticoid receptor as add-on treatment in depression: a randomized, double-blind, placebo-controlled proof-of-concept study.

The selective serotonin re-uptake inhibitor escitalopram modulates the panic response to cholecystokinin tetrapeptide in healthy men depending on 5-HTTLPR genotype.

A combined dexamethasone/corticotropin-releasing hormone test in patients with chronic PTSD--first preliminary results.

No effect of six weeks of treatment with escitalopram on mood in healthy volunteers--irrespective of genotype for the promoter of the serotonin transporter.

Blockade of the mineralocorticoid receptor in healthy men: effects on experimentally induced panic symptoms, stress hormones, and cognition.

Mineralocorticoid receptor function in posttraumatic stress disorder after pretreatment with metyrapone.

Overnight metyrapone and combined dexamethasone/metyrapone tests in post-traumatic stress disorder: preliminary findings.

Valproate monotherapy in the treatment of civilian patients with non-combat-related posttraumatic stress disorder: an open-label study.

Metyrapone tests in patients with panic disorder.

Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial.

The mineralocorticoid receptor agonist, fludrocortisone, inhibits pituitary-adrenal activity in humans after pre-treatment with metyrapone.

Endocrine and cardiovascular responses to corticotropin-releasing hormone in patients with posttraumatic stress disorder: a role for atrial natriuretic peptide?